The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.
Company profile updated October 12, 2026.
Compare the company’s price history and fundamentals in the dashboard. Explore disclosed trading and ownership activity in these research collections: